A once-nightly pill cut breathing interruptions by about 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity. By strengthening the muscles that keep the airway open during sleep, AD109 could offer a new option for people unable to tolerate CPAP.